<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc =20 230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230822140933&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source =镀铬<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20230822140933&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 22 日星期二 18:09:34 +0000</lastbuilddate><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>将患者报告的结果置于心血管临床实践的中心：对护理和管理质量的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>患者报告结果 (PRO) 为了解患者对自身健康和医疗状况的看法提供了重要见解，并且有证据表明，它们的使用可以改善护理质量并做出更明智的临床决策。过去几十年。该声明描述了 PRO 是什么，并提供了针对心血管疾病开发的特定疾病和特定领域 PRO 的清单…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 22 日：ehad514。doi：10.1093/eurheartj/ehad514。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">患者报告结果 (PRO) 为了解患者对自身健康和医疗状况的看法提供了重要见解，并且有证据表明，它们的使用可以改善护理质量并做出更明智的临床决策。该声明描述了 PRO 是什么，并提供了针对心血管人群开发的针对特定疾病和特定领域的 PRO 的清单。国际标准和质量指数已经发布，可以指导针对心血管人群的 PRO 的选择。临床实践以及临床试验和研究；患者以及心理测量学专家应参与选择最合适的方案。需要合作来定义使用 PRO 来指导监管决策的标准，以及 PRO 比较和监测的效用应该评估护理质量和资源分配。记录 PRO 的新来源包括可穿戴数字健康设备、医疗登记和电子健康记录。为心血管医学共享临床决策中 PRO 的最佳使用提供建议，以及关于其更广泛应用的未来方向。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37606064</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad514>10.1093/eurheartj/ehad514</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37606064</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>菲利普·穆恩斯</dc:creator><dc:creator>托恩·M·诺雷克瓦尔</dc:creator><dc:creator>埃琳娜·阿贝洛</dc:creator><dc:creator>布里特·博雷加德</dc:creator><dc:creator>芭芭拉·卡萨迪</dc:creator><dc:creator>伯纳德·科辛斯</dc:creator><dc:creator>马丁·R·考伊</dc:creator><dc:creator>唐娜·菲茨西蒙斯</dc:creator><dc:creator>艾伦·弗雷泽</dc:creator><dc:creator>小贾斯玛</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:creator>何塞帕·毛里</dc:creator><dc:creator>——理查德·明德姆</dc:creator><dc:creator>朱莉·桑德斯</dc:creator><dc:creator>弗朗索瓦·席勒</dc:creator><dc:creator>亚历山大·托比卡</dc:creator><dc:creator>——安·多尔特·兹维斯勒</dc:creator><dc:date>2023-08-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>将患者报告的结果置于心血管临床实践的中心：对护理和管理质量的影响</dc:title><dc:identifier>下午：37606064</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad514</dc:identifier></item><item><title>大脑 α2δ-1 结合 NMDA 受体驱动钙调神经磷酸酶抑制剂诱发的高血压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>结论：这些发现表明，α2δ-1 对于钙调神经磷酸酶抑制剂诱导的 PVN 前交感神经元和交感神经流出突触 NMDAR 活性的增加至关重要。因此，α2δ-1 和 α2δ-1 结合的 NMDAR 代表了治疗钙调神经磷酸酶抑制剂诱导的突触 NMDAR 活性的新靶点。高血压。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 22 日。doi：10.1161/CIRCRESAHA.123.322562。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：钙调磷酸酶在免疫 T 细胞和神经系统中高度富集。钙调磷酸酶抑制剂，包括环孢素和他克莫司 (FK506)，是保护移植器官和组织的免疫抑制方案的基石。过量的交感神经流出，由 N- 维持甲基-D-天冬氨酸受体 (NMDAR) 介导的下丘脑室旁核 (PVN) 兴奋性输入。目前尚不清楚钙调神经磷酸酶抑制剂如何增加 PVN 中的 NMDAR 活性以增强交感血管舒缩活性。α2δ-1（由<i>Cacna2d1</i>基因编码）通俗地称为钙通道亚基，是一种新发现的 NMDAR 相互作用蛋白。在这里，我们确定了 α2δ-1 是否在钙调磷酸酶抑制剂诱导的 PVN 和高血压发展中的突触 NMDAR 过度活跃中发挥作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：免疫印迹和免疫共沉淀分析表明，长期使用 FK506 治疗大鼠可显着增加 PVN 突触体中 α2δ-1、GluN1（必需的 NMDAR 亚基）和 α2δ-1-GluN1 复合物的蛋白水平。加巴喷丁或中断 α2δ-1-NMDAR 与 α2δ-1 C 末端肽的相互作用。脑切片中的全细胞记录表明，FK506 治疗增强了脊髓投射 PVN 神经元中突触前和突触后 NMDAR 的活性，这种作用被消除加巴喷丁、 <i>Cacna2d1</i>敲除或 α2δ-1 C 末端肽。值得注意的是，遥测记录表明，同时给予加巴喷丁可预防 FK506 诱导的大鼠高血压的发生。此外，FK506 治疗可在野生型小鼠中诱导持续性高血压，但在野生型小鼠中则不然。 <i>Cacna2d1</i>基因敲除小鼠。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现表明，α2δ-1 对于钙调神经磷酸酶抑制剂诱导的 PVN 前交感神经元和交感神经流出突触 NMDAR 活性的增加至关重要。因此，α2δ-1 和 α2δ-1 结合的 NMDAR 代表了治疗钙调神经磷酸酶抑制剂诱导的突触 NMDAR 活性的新靶点。高血压。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37605933</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322562>10.1161/CIRCRESAHA.123.322562</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37605933</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>周晶晶</dc:creator><dc:creator>邵建英</dc:creator><dc:creator>陈少瑞</dc:creator><dc:creator>潘慧琳</dc:creator><dc:date>2023-08-22</dc:date><dc:source>流通研究</dc:source><dc:title>大脑 α2δ-1 结合 NMDA 受体驱动钙调神经磷酸酶抑制剂诱发的高血压</dc:title><dc:identifier>下午：37605933</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322562</dc:identifier></item><item><title>盐皮质激素受体拮抗剂联合钠-葡萄糖协同转运蛋白 2 抑制剂治疗心力衰竭：一项荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>结论：MRA 并不影响 SGLT2i 对 HHF/CVD、HHF 或全因死亡率的综合作用；然而，研究结果暗示，慢性心力衰竭患者的 CVD 相对降低更为显着，无论 EF 情况如何，这些患者随机接受 SGLT2i 治疗并接受MRA 与那些随机接受 SGLT2i 且未接受 MRA 的患者相比。SGLT2i 降低了 MRA 相关治疗引起的高钾血症的风险。这些发现值得在精心设计的随机对照试验中得到进一步验证。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 22 日：ehad522。doi：10.1093/eurheartj/ehad522。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：研究钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 与盐皮质激素受体拮抗剂 (MRA) 联合使用对心力衰竭 (HF) 的心血管影响，无论射血分数 (EF) 如何，并探讨 MRA 的风险随机接受 SGLT2i 与安慰剂组的个体的相关不良事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 PubMed/MEDLINE、Web of Science、Embase 和临床试验注册中心中检索评估 SGLT2i 在使用或不使用 MRA 的情况下治疗心力衰竭的随机对照试验/事后分析（PROSPERO：CRD42023397129）。或因心力衰竭/心血管死亡而紧急就诊(HHF/CVD)、HHF 和 CVD。其他为全因死亡率、复合肾脏和安全性结果。提取风险比 (HR)/风险比。进行固定效应荟萃分析和亚组分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：纳入了五项符合条件的研究，汇集了 21 947 名 HF 患者（2 型糖尿病，n = 10 805）的数据。与安慰剂相比，SGLT2i 的随机分组显示，患有或患有 HF 的患者的 HHF/CVD 和 HHF 有类似的减少。未使用 MRA [HHF/CVD：风险比 (HR) 0.75；95% 置信区间 (CI) 0.68-0.81 vs. HR 0.79；95% CI 0.72-0.86；P 交互作用 = 0.43；HHF：HR 0.74； 95% CI 0.67-0.83 对比 HR 0.71；95% CI 0.63-0.80；P 交互作用 = .53]，这表明随机接受 SGLT2i 并使用 MRA 的慢性心力衰竭患者的 CVD 相对减少较多，与 EF 无关（HR 95% CI 0.72-0.91 对比 HR 0.98；95% CI 0.86-1.13；P 交互作用 = .034）。SGLT2i 降低全因死亡率（P 交互作用 = .27）和不良肾脏终点，无论 MRA 使用情况如何 SGLT2i 减弱轻度高钾血症（P-相互作用 &lt; .001）和重度高钾血症（P-相互作用 = .001）的风险，尽管与 MRA 使用相关的伴随 MRA 容量不足的风险较高（P-相互作用 = .082）。0.051） 。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：MRA 并不影响 SGLT2i 对 HHF/CVD、HHF 或全因死亡率的综合作用；然而，研究结果暗示，慢性心力衰竭患者的 CVD 相对降低更为显着，无论 EF 情况如何，这些患者随机接受 SGLT2i 治疗并接受MRA 与那些随机接受 SGLT2i 且未接受 MRA 的患者相比。SGLT2i 降低了 MRA 相关治疗引起的高钾血症的风险。这些发现值得在精心设计的随机对照试验中进一步验证。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37605637</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad522>10.1093/eurheartj/ehad522</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37605637</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>迈纳克·班纳吉</dc:creator><dc:creator>英迪拉·迈斯南</dc:creator><dc:creator>里梅什·帕尔</dc:creator><dc:creator>萨蒂娜·穆霍帕迪亚</dc:creator><dc:date>2023-08-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>盐皮质激素受体拮抗剂联合钠-葡萄糖协同转运蛋白 2 抑制剂治疗心力衰竭：一项荟萃分析</dc:title><dc:identifier>下午：37605637</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad522</dc:identifier></item><item><title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):e8.doi: 10.1161/CIR.0000000000001177. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603606</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001177>10.1161/CIR.0000000000001177</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603606</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:date> 2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</dc:title><dc:identifier>下午：37603606</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001177</dc:identifier></item><item><title>二叶式主动脉瓣和胸主动脉疾病：临床上对受影响个体的家庭成员无声但致命的风险的进一步证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):648-650. doi: 10.1161/CIRCULATIONAHA.123.06540​​6. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603605</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065406>10.1161/CIRCULATIONAHA.123.06540​​6</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603605</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>悉达多·K·普拉卡什</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:creator>戴安娜·米勒维奇</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>二叶式主动脉瓣和胸主动脉疾病：临床上对受影响个体的家庭成员无声但致命的风险的进一步证据</dc:title><dc:identifier>下午：37603605</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.06540​​6</dc:identifier></item><item><title>心脏移植分子诊断的选择和解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>美国和全世界每年进行的心脏移植手术数量持续增加，但过去 20 年来移植物寿命和患者生存率几乎没有变化。诊断急性细胞和抗体介导的排斥反应的参考标准包括组织学检查心内膜心肌活检样本的免疫荧光评估和免疫荧光评估，尽管组织学排斥反应分级具有侵入性和较高的受试者间变异性。循环生物标志物和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):679-694. doi: 10.1161/CIRCULATIONAHA.123.062847. Epub 2023 年 8 月 21 日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">美国和全世界每年进行的心脏移植手术数量持续增加，但过去 20 年来移植物寿命和患者生存率几乎没有变化。诊断急性细胞和抗体介导的排斥反应的参考标准包括组织学检查心内膜心肌活检样本的免疫荧光评估，尽管具有侵入性和对组织学排斥进行分级的高人间变异性。循环生物标志物和分子诊断在排斥监测中显示出巨大的预测价值，并且新出现的数据支持它们在诊断其他移植后并发症中的使用。无细胞DNA） 、转录组学（mRNA 和 microRNA 分析）和蛋白质组学（蛋白质表达定量）方法诊断这些移植后结果已通过不同程度的证据进行了评估。排斥（免疫遗传学）增强了对抗体介导的排斥、相关移植物功能障碍和死亡。针对供者人类白细胞抗原的抗体以及可用于评估这些抗体的技术不断发展。用于诊断移植后并发症。这包括对儿科心脏移植的讨论以及接受心脏移植的黑人患者经历的不同的排斥率和死亡率. 这篇综述描述了移植后可用和使用的诊断方式，以及提高移植后患者预后所需的未来研究前景。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603604</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.062847>10.1161 / CIRCULATIONAHA.123.062847</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603604</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——贾森·F·戈德堡</dc:creator><dc:creator>劳伦·特鲁比</dc:creator><dc:creator>肖恩·阿格博-伊诺</dc:creator><dc:creator>——安妮特·M·杰克逊</dc:creator><dc:creator>克里斯托弗·R·德菲利皮</dc:creator><dc:creator>Kiran K Khush更多</dc:creator><dc:creator>帕拉克·沙阿</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>心脏移植分子诊断的选择和解释</dc:title><dc:identifier>下午：37603604</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.062847</dc:identifier></item><item><title>乙醇诱发的心房颤动由晚期 &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; 引起，可用雷诺嗪预防</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):698-700. doi: 10.1161/CIRCULATIONAHA.123.064561. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603603</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064561>10.1161 / CIRCULATIONAHA.123.064561</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603603</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱利安·穆斯特罗夫</dc:creator><dc:creator>玛丽亚·J·拜尔</dc:creator><dc:creator>丹尼斯·温辛</dc:creator><dc:creator>兹德内克·普罗瓦兹尼克</dc:creator><dc:creator>科斯坦丁·科扎科夫</dc:creator><dc:creator>西蒙·勒贝克</dc:creator><dc:creator>丹尼尔·塔尔诺夫斯基</dc:creator><dc:creator>松克·希尔特</dc:creator><dc:creator>尼尔斯·沃伊特</dc:creator><dc:creator>斯特凡·瓦格纳</dc:creator><dc:creator>拉斯·迈尔</dc:creator><dc:creator>斯特凡·尼夫</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>乙醇诱发的心房颤动由晚期 &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; 引起，可用雷诺嗪预防</dc:title><dc:identifier>下午：37603603</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064561</dc:identifier></item><item><title> Teng 等人关于文章“肠道微生物衍生的三甲胺 N-氧化物通过炎症和凋亡机制导致腹主动脉瘤”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):701-702. doi: 10.1161/CIRCULATIONAHA.123.065557. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603602</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065557>10.1161/CIRCULATIONAHA.123.065557</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603602</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>滕振清</dc:creator><dc:creator>向马</dc:creator><dc:creator>马一桐</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>Teng 等人关于文章“肠道微生物衍生的三甲胺 N-氧化物通过炎症和凋亡机制导致腹主动脉瘤”的信函</dc:title><dc:identifier>下午：37603602</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065557</dc:identifier></item><item><title>排尿晕厥……并不总是良性的</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603601/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):695-697. doi: 10.1161/CIRCULATIONAHA.123.066038. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603601/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603601</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066038>10.1161 / CIRCULATIONAHA.123.066038</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603601</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>穆尼姆·阿里·汗</dc:creator><dc:creator>萨米·维斯金</dc:creator><dc:creator>克里斯托弗·马迪亚斯</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>排尿晕厥……并不总是良性的</dc:title><dc:identifier>下午：37603601</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066038</dc:identifier></item><item><title>心肾生物标志物、卡格列净和糖尿病肾病的结果：CREDENCE 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603600/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>结论：多种心肾应激生物标志物对患有 2 型糖尿病和白蛋白尿的患者具有很强的预后作用。卡格列净适度降低了每种生物标志物上升的纵向轨迹。除基线水平外，生物标志物水平的变化增强了主要结果预测。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):651-660. doi: 10.1161/CIRCULATIONAHA.123.065251. Epub 2023 年 8 月 21 日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：患有蛋白尿的 2 型糖尿病患者发生心脏和肾脏事件的风险较高。帮助疾病预测和了解钠-葡萄糖协同转运蛋白 2 抑制的益处的最佳生物标志物仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 CREDENCE 试验（卡格列净和糖尿病肾病临床评估中的肾脏事件）的 2627 名研究参与者中，检测 NT-proBNP（N 末端 B 型利钠肽前体）浓度、高敏心肌肌钙蛋白 T、生长情况测量分化因子 15 和 IGFBP7（胰岛素样生长因子结合蛋白 7）。评估卡格列净对生物标志物浓度的影响。透析、移植或持续估计肾小球滤过率 &lt;15 mL min <sup>-1</sup> 1.73 m <sup>-2</sup> ]，血清肌酐水平加倍，或肾死亡或心血管死亡）进行了评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：每种生物标志物的中位（四分位数 1 和 3）浓度普遍升高：NT-proBNP，180 ng/L (82, 442 ng/L)；高敏心肌肌钙蛋白 T，19 ng/L (12, 29 ng/L)；生长分化因子-15，2595 ng/L (1852, 3775 ng/L)；IGFBP7，121.8 ng/mL (105.4, 141.5 ng/mL)。1 年时，生物标志物全部上升了 6安慰剂组中的 % 至 29%，但卡格列净组中仅为 3% 至 10%（多变量线性混合效应模型中所有<i>P</i> &lt;0.01）。每种生物标志物的基线浓度对心脏和肾脏结果具有很强的预测作用。在多标志物面板中对具有高风险评分（风险比 [HR]，4.01 [95% CI，2.52-6.35]）和中等风险评分（HR，2.39 [95% CI，1.48-3.87]）的个体进行一起分析。与低风险评分的患者相比，主要结局的风险更高。到 1 年，NT-proBNP (HR, 1.11 [95% CI, 1.08-1.15])、高敏心肌肌钙蛋白 T ( HR ，1.86 [95% CI，1.64-2.10]）、生长分化因子 15（HR，1.45 [95% CI，1.24-1.70]）和 IGFBP7（HR，3.76 [95% CI，2.54-5.56]）与主要结局的风险相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：多种心肾应激生物标志物对患有 2 型糖尿病和白蛋白尿的患者具有很强的预后作用。卡格列净适度降低了每种生物标志物上升的纵向轨迹。除基线水平外，生物标志物水平的变化增强了主要结果预测。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT02065791。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603600/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37603600</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065251>10.1161/CIRCULATIONAHA.123.065251</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603600</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>詹姆斯·贾努齐</dc:creator><dc:creator>礼萨·莫赫比</dc:creator><dc:creator>刘玉玺</dc:creator><dc:creator>纳维德·萨塔尔</dc:creator><dc:creator>希多·JL·赫尔斯平克</dc:creator><dc:creator>埃谢图·泰费拉</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>Yshai Yavin更多</dc:creator><dc:creator>李经纬</dc:creator><dc:creator>卡罗尔·波洛克</dc:creator><dc:creator>弗拉多·佩尔科维奇</dc:creator><dc:creator>布鲁斯·尼尔</dc:creator><dc:creator>——迈克尔·K·汉森</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>心肾生物标志物、卡格列净和糖尿病肾病的结果：CREDENCE 试验</dc:title><dc:identifier>下午：37603600</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065251</dc:identifier></item><item><title>使用单一新型腺相关病毒提供的优化心脏重编程混合物改善缺血后大鼠的心脏功能</title><link/>https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>结论：总的来说，这些结果推进了心脏重编程基因治疗作为治疗缺血性损伤引起的慢性心力衰竭的可行治疗方法的应用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 21 日。doi：10.1161/CIRCULATIONAHA.122.061542。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心脏重编程是一种利用基因或小分子直接将非心肌细胞转化为心肌细胞的技术。这种干预措施在心肌梗塞时进行递送或在心肌梗塞后 4 周内通过转基因激活，可为啮齿类动物的心脏提供功能益处。一些障碍阻碍了心脏重编程临床应用的进展。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过筛选和合理设计相结合，我们确定了一种可以在单一腺相关病毒中编码的心脏重编程混合物，并创建了一种新型腺相关病毒衣壳，它可以比现有的亲本血清型更有效地转导心脏成纤维细胞由于需要组成型启动子来驱动这些改变细胞命运的重编程因子的高表达，因此我们在表达盒的 3&#39; 非翻译区内加入了心肌细胞限制性 microRNA 的结合位点，从而限制了表达在优化该表达盒以在体外将人心脏成纤维细胞重编程为诱导心肌细胞样细胞后，我们还测试了该衣壳/表达盒组合在急性小鼠心肌梗塞和慢性大鼠心肌梗塞模型中赋予功能益处的能力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们在心肌梗死后 2 周治疗大鼠模型时证明了心脏功能的持续、剂量依赖性改善，表明当以单一的、临床相关的腺相关病毒载体进行心脏重编程时，可以支持重构后的功能改善。这种益处在 GFP（绿色荧光蛋白）或肝细胞重编程混合物中没有观察到，甚至在免疫抑制存在的情况下也能实现，支持肌细胞形成作为潜在机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：总的来说，这些结果推进了心脏重编程基因治疗作为治疗缺血性损伤引起的慢性心力衰竭的可行治疗方法的应用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37602409</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061542>10.1161/CIRCULATIONAHA.122.061542</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37602409</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>周环宇</dc:creator><dc:creator>金阳</dc:creator><dc:creator>切坦·斯里纳特</dc:creator><dc:creator>曾阿丽娅</dc:creator><dc:creator>吴虹</dc:creator><dc:creator>埃琳娜·C·莱昂</dc:creator><dc:creator>茶色尼尔·库雷希</dc:creator><dc:creator>——克里斯托弗·A·里德</dc:creator><dc:creator>艾米丽·R·内特斯海姆</dc:creator><dc:creator>徐艾玛</dc:creator><dc:creator>佐伊·杜克洛</dc:creator><dc:creator>塔梅尔·穆罕默德</dc:creator><dc:creator>Farshad Farshidfar更多</dc:creator><dc:creator>安东尼·费杰斯</dc:creator><dc:creator>刘军</dc:creator><dc:creator>——萨曼莎·琼斯</dc:creator><dc:creator>查尔斯·费瑟斯</dc:creator><dc:creator>郑泰元</dc:creator><dc:creator>景弗兰克</dc:creator><dc:creator>威廉·S·普林斯</dc:creator><dc:creator>林建民</dc:creator><dc:creator>于彭志</dc:creator><dc:creator>迪帕克·斯里瓦斯塔瓦</dc:creator><dc:creator>蒂莫西·霍伊</dc:creator><dc:creator>凯瑟琳·N·艾维</dc:creator><dc:creator>劳拉·M·隆巴尔迪</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>使用单一新型腺相关病毒提供的优化心脏重编程混合物改善缺血后大鼠的心脏功能</dc:title><dc:identifier>下午：37602409</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.061542</dc:identifier></item><item><title>分次血流储备引导 PCI 或冠状动脉搭桥手术治疗 3 支冠状动脉疾病：FAME 3 试验的 3 年随访</title><link/>https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>结论：在 3 年随访中，与 CABG 相比，采用当前一代药物洗脱支架进行 FFR 引导 PCI 后死亡、心梗或卒中的复合发生率没有差异。 ，死亡或中风没有差异。这些结果提供了当代数据，可以改善医生和三支冠状动脉疾病患者之间的共同决策。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 21 日。doi：10.1161/CIRCULATIONAHA.123.065770。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：既往研究对不累及左主干的多支冠状动脉疾病患者进行经皮冠状动脉介入治疗 (PCI) 与冠状动脉旁路移植术 (CABG) 的比较，结果显示，CABG 后死亡率、心肌梗死 (MI) 或卒中的发生率显着降低。没有常规使用当前一代药物洗脱支架或血流储备分数 (FFR) 来指导 PCI。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：FAME 3（多支血管评估的血流储备分数与血管造影）是一项由研究者发起的、多中心、国际性、随机试验，涉及全球 48 个中心的 3 支冠状动脉疾病（不涉及左主冠状动脉）患者。随机分配接受使用佐他莫司药物洗脱支架或 CABG 的 FFR 引导 PCI。此处报告的试验的预先指定关键次要终点是死亡、心肌梗死或中风复合终点的 3 年发生率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有1500名患者被随机分配接受FFR引导的PCI或CABG，两组患者均达到96%以上的随访，术后死亡、心梗或卒中的复合发生率无差异。 FFR 引导 PCI 与 CABG 相比（12.0% 对比 9.2%；风险比 [HR]，1.3 [95% CI，0.98-1.83]； <i>P</i> = 0.07）。死亡率（4.1% 对比 3.9%；HR，1.0） ) [95% CI, 0.6-1.7]； <i>P</i> =0.88) 和卒中（1.6% vs 2.0%；HR, 0.8 [95% CI, 0.4-1.7]； <i>P</i> =0.56）没有差异。 PCI（7.0% vs 4.2%；HR，1.7 [95% CI，1.1-2.7]； <i>P</i> = 0.02）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在 3 年随访中，与 CABG 相比，采用当前一代药物洗脱支架进行 FFR 引导 PCI 后死亡、心梗或卒中的复合发生率没有差异。 ，死亡或中风没有差异。这些结果提供了当代数据，可以改善医生和三支冠状动脉疾病患者之间的共同决策。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT02100722。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37602376</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065770>10.1161/CIRCULATIONAHA.123.065770</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37602376</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗雷德里克·M·齐默尔曼</dc:creator><dc:creator>丁维多利亚</dc:creator><dc:creator>尼科·H·J·皮尔斯</dc:creator><dc:creator>兹索尔特·皮罗斯</dc:creator><dc:creator>阿尔伯特·HM·范·斯特拉滕</dc:creator><dc:creator>拉斯洛·塞克利</dc:creator><dc:creator>吉德里乌斯·达维修斯</dc:creator><dc:creator>金塔拉斯·卡利瑙斯卡斯</dc:creator><dc:creator>萨默·曼苏尔</dc:creator><dc:creator>拉杰什·卡班达</dc:creator><dc:creator>尼古拉斯·奥斯特伦德-帕帕多格奥尔戈斯</dc:creator><dc:creator>阿黛尔·阿米尼安</dc:creator><dc:creator>基思·奥尔德罗伊德</dc:creator><dc:creator>纳瓦尔·阿塔尔</dc:creator><dc:creator>尼古拉·贾吉克更多</dc:creator><dc:creator>扬-亨克·E·丹布林克</dc:creator><dc:creator>彼得·卡拉</dc:creator><dc:creator>奥斯卡·安吉拉斯更多</dc:creator><dc:creator>菲利普·麦卡锡</dc:creator><dc:creator>奥拉夫·温德勒</dc:creator><dc:creator>菲利普·卡塞尔曼</dc:creator><dc:creator>尼尔斯·维特</dc:creator><dc:creator>克雷顿·马夫罗马蒂斯</dc:creator><dc:creator>史蒂文·ES·迈纳</dc:creator><dc:creator>杰迪普·萨尔玛</dc:creator><dc:creator>托马斯·恩斯特罗姆</dc:creator><dc:creator>埃瓦尔德·H·克里斯蒂安森</dc:creator><dc:creator>Pim AL Tonino更多</dc:creator><dc:creator>——迈克尔·J·里尔登</dc:creator><dc:creator>大月久男</dc:creator><dc:creator>小林佑平</dc:creator><dc:creator>马克·A·赫拉基</dc:creator><dc:creator>——肯尼思·W·马哈菲</dc:creator><dc:creator>Manisha Desai更多</dc:creator><dc:creator>吴宇森</dc:creator><dc:creator>杨志雄</dc:creator><dc:creator>伯纳德·德布劳内</dc:creator><dc:creator>威廉·费伦</dc:creator><dc:creator>FAME 3 调查员</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>分次血流储备引导 PCI 或冠状动脉搭桥手术治疗 3 支冠状动脉疾病：FAME 3 试验的 3 年随访</dc:title><dc:identifier>下午：37602376</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065770</dc:identifier></item><item><title>癫痫和心律失常的长期风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230822140933&amp;v=2.17.9.post6+86293ac<description>结论：这项研究表明，癫痫患者长期存在心律失常的较高风险，尤其是使用卡马西平和丙戊酸的患者。这些发现强调了癫痫患者需要定期监测和管理心律，以降低风险进一步的心血管并发症。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 21 日：ehad523。doi：10.1093/eurheartj/ehad523。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：先前的证据主要支持癫痫患者在发作间期或围发作期心功能发生短暂变化，但对心律失常的长期风险描述甚少。观察到的任何关联中的易感性和抗癫痫药物（ASM）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项基于人群的研究评估了 2006 年至 2010 年间招募的英国生物银行数据。Cox 比例风险模型和竞争风险模型用于检查癫痫病史与心律失常和心律失常亚型的长期发病风险之间的关联。计算多基因风险评分 (PRS) 来研究遗传易感性的影响。还通过整合观察和药物靶点孟德尔随机化 (MR) 证据来评估 ASM 的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：该研究纳入了 329 432 人，其中 2699 名癫痫患者。与非癫痫患者相比，癫痫患者发生所有心律失常的风险均增加[风险比 (HR) 1.36，95% 置信区间 (CI) 1.21-1.53 ]、心房颤动（HR 1.26，95% CI 1.08-1.46）和其他心律失常（HR 1.56，95% CI 1.34-1.81）。这些关联并未因 PRS 所示的遗传易感性而改变。竞争分析和敏感性分析证实了使用 ASM（尤其是卡马西平和丙戊酸）的癫痫患者发生心律失常的风险较高。药物靶点 MR 结果进一步支持了这一观察结果（PSMR &lt; .05 和 PHEIDI >; .05）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37602368</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad523>10.1093/eurheartj/ehad523</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37602368</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jie Wang</dc:creator><dc:creator> Peiyuan Huang</dc:creator><dc:creator> Qingwei Yu</dc:creator><dc:creator> Jun Lu</dc:creator><dc:creator> Pinbo Liu</dc:creator><dc:creator> Yiping Yang</dc:creator><dc:creator> Zeying Feng</dc:creator><dc:creator> Jingjing Cai</dc:creator><dc:creator> Guoping Yang</dc:creator><dc:creator> Hong Yuan</dc:creator><dc:creator> Haibo Tang</dc:creator><dc:creator> Yao Lu</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> European heart journal</dc:source><dc:title> Epilepsy and long-term risk of arrhythmias</dc:title><dc:identifier> pmid:37602368</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad523</dc:identifier></item><item><title> Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</title><link/> https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 21:ehad484. doi: 10.1093/eurheartj/ehad484. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a consensus definition of PVAT around the coronary arteries, as the AT surrounding the artery up to a distance from its outer wall equal to the luminal diameter of the artery. Special focus is given to the interactions between PVAT and the vascular wall that render PVAT a potential therapeutic target in cardiovascular diseases. This Clinical Consensus Statement also discusses the role of PVAT as a clinically relevant source of diagnostic and prognostic biomarkers of vascular function, which may guide precision medicine in atherosclerosis, hypertension, heart failure, and other cardiovascular diseases. In this article, its role as a &#39;biosensor&#39; of vascular inflammation is highlighted with description of recent imaging technologies that visualize PVAT in clinical practice, allowing non-invasive quantification of coronary inflammation and the related residual cardiovascular inflammatory risk, guiding deployment of therapeutic interventions. Finally, the current and future clinical applicability of artificial intelligence and machine learning technologies is reviewed that integrate PVAT information into prognostic models to provide clinically meaningful information in primary and secondary prevention.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37599464</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad484>10.1093/eurheartj/ehad484</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37599464</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Charalambos Antoniades</dc:creator><dc:creator> Dimitris Tousoulis</dc:creator><dc:creator> Marija Vavlukis</dc:creator><dc:creator> Ingrid Fleming</dc:creator><dc:creator> Dirk J Duncker</dc:creator><dc:creator> Etto Eringa</dc:creator><dc:creator> Olivia Manfrini</dc:creator><dc:creator> Alexios S Antonopoulos</dc:creator><dc:creator> Evangelos Oikonomou</dc:creator><dc:creator> Teresa Padró</dc:creator><dc:creator> Danijela Trifunovic-Zamaklar</dc:creator><dc:creator> Giuseppe De Luca</dc:creator><dc:creator> Tomasz Guzik</dc:creator><dc:creator> Edina Cenko</dc:creator><dc:creator> Ana Djordjevic-Dikic</dc:creator><dc:creator> Filippo Crea</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> European heart journal</dc:source><dc:title> Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</dc:title><dc:identifier> pmid:37599464</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad484</dc:identifier></item><item><title> Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</title><link/> https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 15:S0092-8674(23)00796-1. doi: 10.1016/j.cell.2023.07.019. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and epigenetic programs of HSPC persisted for months to 1 year following severe COVID-19 and were associated with distinct transcription factor (TF) activities, altered regulation of inflammatory programs, and durable increases in myelopoiesis. HSPC epigenomic alterations were conveyed, through differentiation, to progeny innate immune cells. Early activity of IL-6 contributed to these persistent phenotypes in human COVID-19 and a mouse coronavirus infection model. Epigenetic reprogramming of HSPC may underlie altered immune function following infection and be broadly relevant, especially for millions of COVID-19 survivors.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37597510</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.019>10.1016/j.cell.2023.07.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37597510</guid><pubDate> Sat, 19 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jin-Gyu Cheong</dc:creator><dc:creator> Arjun Ravishankar</dc:creator><dc:creator> Siddhartha Sharma</dc:creator><dc:creator> Christopher N Parkhurst</dc:creator><dc:creator> Simon A Grassmann</dc:creator><dc:creator> Claire K Wingert</dc:creator><dc:creator> Paoline Laurent</dc:creator><dc:creator> Sai Ma</dc:creator><dc:creator> Lucinda Paddock</dc:creator><dc:creator> Isabella C Miranda</dc:creator><dc:creator> Emin Onur Karakaslar</dc:creator><dc:creator> Djamel Nehar-Belaid</dc:creator><dc:creator> Asa Thibodeau</dc:creator><dc:creator> Michael J Bale</dc:creator><dc:creator> Vinay K Kartha</dc:creator><dc:creator> Jim K Yee</dc:creator><dc:creator> Minh Y Mays</dc:creator><dc:creator> Chenyang Jiang</dc:creator><dc:creator> Andrew W Daman</dc:creator><dc:creator> Alexia Martinez de Paz</dc:creator><dc:creator> Dughan Ahimovic</dc:creator><dc:creator> Victor Ramos</dc:creator><dc:creator> Alexander Lercher</dc:creator><dc:creator> Erik Nielsen</dc:creator><dc:creator> Sergio Alvarez-Mulett</dc:creator><dc:creator> Ling Zheng</dc:creator><dc:creator> Andrew Earl</dc:creator><dc:creator> Alisha Yallowitz</dc:creator><dc:creator> Lexi Robbins</dc:creator><dc:creator> Elyse LaFond</dc:creator><dc:creator> Karissa L Weidman</dc:creator><dc:creator> Sabrina Racine-Brzostek</dc:creator><dc:creator> He S Yang</dc:creator><dc:creator> David R Price</dc:creator><dc:creator> Louise Leyre</dc:creator><dc:creator> André F Rendeiro</dc:creator><dc:creator> Hiranmayi Ravichandran</dc:creator><dc:creator> Junbum Kim</dc:creator><dc:creator> Alain C Borczuk</dc:creator><dc:creator> Charles M Rice</dc:creator><dc:creator> R Brad Jones</dc:creator><dc:creator> Edward J Schenck</dc:creator><dc:creator> Robert J Kaner</dc:creator><dc:creator> Amy Chadburn</dc:creator><dc:creator> Zhen Zhao</dc:creator><dc:creator> Virginia Pascual</dc:creator><dc:creator> Olivier Elemento</dc:creator><dc:creator> Robert E Schwartz</dc:creator><dc:creator> Jason D Buenrostro</dc:creator><dc:creator> Rachel E Niec</dc:creator><dc:creator> Franck J Barrat</dc:creator><dc:creator> Lindsay Lief</dc:creator><dc:creator> Joseph C Sun</dc:creator><dc:creator> Duygu Ucar</dc:creator><dc:creator> Steven Z Josefowicz</dc:creator><dc:date> 2023-08-19</dc:date><dc:source> Cell</dc:source><dc:title> Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</dc:title><dc:identifier> pmid:37597510</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.019</dc:identifier></item><item><title> Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</title><link/> https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 19:ehad527. doi: 10.1093/eurheartj/ehad527. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37596979</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad527>10.1093/eurheartj/ehad527</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37596979</guid><pubDate> Sat, 19 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Steven E Nissen</dc:creator><dc:date> 2023-08-19</dc:date><dc:source> European heart journal</dc:source><dc:title> Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</dc:title><dc:identifier> pmid:37596979</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad527</dc:identifier></item><item><title> Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin</title><link/> https://pubmed.ncbi.nlm.nih.gov/37595566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role in liver cancer remains elusive. Here, we present a MAIT cell-centered profiling of hepatocellular carcinoma (HCC) using scRNA-seq, flow cytometry, and co-detection by indexing (CODEX) imaging of paired patient samples. These analyses highlight the heterogeneity and dysfunctionality of MAIT... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 17;186(17):3686-3705.e32. doi: 10.1016/j.cell.2023.07.026.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role in liver cancer remains elusive. Here, we present a MAIT cell-centered profiling of hepatocellular carcinoma (HCC) using scRNA-seq, flow cytometry, and co-detection by indexing (CODEX) imaging of paired patient samples. These analyses highlight the heterogeneity and dysfunctionality of MAIT cells in HCC and their defective capacity to infiltrate liver tumors. Machine-learning tools were used to dissect the spatial cellular interaction network within the MAIT cell neighborhood. Co-localization in the adjacent liver and interaction between niche-occupying CSF1R <sup>+</sup> PD-L1 <sup>+</sup> tumor-associated macrophages (TAMs) and MAIT cells was identified as a key regulatory element of MAIT cell dysfunction. Perturbation of this cell-cell interaction in ex vivo co-culture studies using patient samples and murine models reinvigorated MAIT cell cytotoxicity. These studies suggest that aPD-1/aPD-L1 therapies target MAIT cells in HCC patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37595566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37595566</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.026>10.1016/j.cell.2023.07.026</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37595566</guid><pubDate> Fri, 18 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Benjamin Ruf</dc:creator><dc:creator> Matthias Bruhns</dc:creator><dc:creator> Sepideh Babaei</dc:creator><dc:creator> Noemi Kedei</dc:creator><dc:creator> Lichun Ma</dc:creator><dc:creator> Mahler Revsine</dc:creator><dc:creator> Mohamed-Reda Benmebarek</dc:creator><dc:creator> Chi Ma</dc:creator><dc:creator> Bernd Heinrich</dc:creator><dc:creator> Varun Subramanyam</dc:creator><dc:creator> Jonathan Qi</dc:creator><dc:creator> Simon Wabitsch</dc:creator><dc:creator> Benjamin L Green</dc:creator><dc:creator> Kylynda C Bauer</dc:creator><dc:creator> Yuta Myojin</dc:creator><dc:creator> Layla T Greten</dc:creator><dc:creator> Justin D McCallen</dc:creator><dc:creator> Patrick Huang</dc:creator><dc:creator> Rajiv Trehan</dc:creator><dc:creator> Xin Wang</dc:creator><dc:creator> Amran Nur</dc:creator><dc:creator> Dana Qiang Murphy Soika</dc:creator><dc:creator> Marie Pouzolles</dc:creator><dc:creator> Christine N Evans</dc:creator><dc:creator> Raj Chari</dc:creator><dc:creator> David E Kleiner</dc:creator><dc:creator> William Telford</dc:creator><dc:creator> Kimia Dadkhah</dc:creator><dc:creator> Allison Ruchinskas</dc:creator><dc:creator> Merrill K Stovroff</dc:creator><dc:creator> Jiman Kang</dc:creator><dc:creator> Kesha Oza</dc:creator><dc:creator> Mathuros Ruchirawat</dc:creator><dc:creator> Alexander Kroemer</dc:creator><dc:creator> Xin Wei Wang</dc:creator><dc:creator> Manfred Claassen</dc:creator><dc:creator> Firouzeh Korangy</dc:creator><dc:creator> Tim F Greten</dc:creator><dc:date> 2023-08-18</dc:date><dc:source> Cell</dc:source><dc:title> Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin</dc:title><dc:identifier> pmid:37595566</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.026</dc:identifier></item><item><title> A conserved family of immune effectors cleaves cellular ATP upon viral infection</title><link/> https://pubmed.ncbi.nlm.nih.gov/37595565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> During viral infection, cells can deploy immune strategies that deprive viruses of molecules essential for their replication. Here, we report a family of immune effectors in bacteria that, upon phage infection, degrade cellular adenosine triphosphate (ATP) and deoxyadenosine triphosphate (dATP) by cleaving the N-glycosidic bond between the adenine and sugar moieties. These ATP nucleosidase effectors are widely distributed within multiple bacterial defense systems, including cyclic... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 17;186(17):3619-3631.e13. doi: 10.1016/j.cell.2023.07.020.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> During viral infection, cells can deploy immune strategies that deprive viruses of molecules essential for their replication. Here, we report a family of immune effectors in bacteria that, upon phage infection, degrade cellular adenosine triphosphate (ATP) and deoxyadenosine triphosphate (dATP) by cleaving the N-glycosidic bond between the adenine and sugar moieties. These ATP nucleosidase effectors are widely distributed within multiple bacterial defense systems, including cyclic oligonucleotide-based antiviral signaling systems (CBASS), prokaryotic argonautes, and nucleotide-binding leucine-rich repeat (NLR)-like proteins, and we show that ATP and dATP degradation during infection halts phage propagation. By analyzing homologs of the immune ATP nucleosidase domain, we discover and characterize Detocs, a family of bacterial defense systems with a two-component phosphotransfer-signaling architecture. The immune ATP nucleosidase domain is also encoded within diverse eukaryotic proteins with immune-like architectures, and we show biochemically that eukaryotic homologs preserve the ATP nucleosidase activity. Our findings suggest that ATP and dATP degradation is a cell-autonomous innate immune strategy conserved across the tree of life.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37595565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37595565</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.020>10.1016/j.cell.2023.07.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37595565</guid><pubDate> Fri, 18 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Francois Rousset</dc:creator><dc:creator> Erez Yirmiya</dc:creator><dc:creator> Shahar Nesher</dc:creator><dc:creator> Alexander Brandis</dc:creator><dc:creator> Tevie Mehlman</dc:creator><dc:creator> Maxim Itkin</dc:creator><dc:creator> Sergey Malitsky</dc:creator><dc:creator> Adi Millman</dc:creator><dc:creator> Sarah Melamed</dc:creator><dc:creator> Rotem Sorek</dc:creator><dc:date> 2023-08-18</dc:date><dc:source> Cell</dc:source><dc:title> A conserved family of immune effectors cleaves cellular ATP upon viral infection</dc:title><dc:identifier> pmid:37595565</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.020</dc:identifier></item><item><title> An ethical framework for human embryology with embryo models</title><link/> https://pubmed.ncbi.nlm.nih.gov/37595564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> A human embryo&#39;s legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest &quot;tipping points&quot; for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 17;186(17):3548-3557. doi: 10.1016/j.cell.2023.07.028.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> A human embryo&#39;s legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest &quot;tipping points&quot; for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles that might help to draft a roadmap for the gradual, justified usage of embryo models in a manner that aims to maximize benefits to society.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37595564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37595564</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.028>10.1016/j.cell.2023.07.028</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37595564</guid><pubDate> Fri, 18 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Nicolas C Rivron</dc:creator><dc:creator> Alfonso Martinez Arias</dc:creator><dc:creator> Martin F Pera</dc:creator><dc:creator> Naomi Moris</dc:creator><dc:creator> Hafez Ismaili M&#39;hamdi</dc:creator><dc:date> 2023-08-18</dc:date><dc:source> Cell</dc:source><dc:title> An ethical framework for human embryology with embryo models</dc:title><dc:identifier> pmid:37595564</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.028</dc:identifier></item><item><title> Insights and strategies for improving equity in graduate school admissions</title><link/> https://pubmed.ncbi.nlm.nih.gov/37595563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> Applying to graduate school can be particularly challenging for students from historically minoritized backgrounds due to a hidden curriculum in the graduate admissions process. To address this issue, a team of volunteer STEM trainees established the Científico Latino Graduate Student Mentorship Initiative (CL-GSMI) in 2019 to support applicants from historically minoritized backgrounds. CL-GSMI is designed to improve access to critical resources, including information, mentorship, and financial... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 17;186(17):3529-3547. doi: 10.1016/j.cell.2023.07.029.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Applying to graduate school can be particularly challenging for students from historically minoritized backgrounds due to a hidden curriculum in the graduate admissions process. To address this issue, a team of volunteer STEM trainees established the Científico Latino Graduate Student Mentorship Initiative (CL-GSMI) in 2019 to support applicants from historically minoritized backgrounds. CL-GSMI is designed to improve access to critical resources, including information, mentorship, and financial support, and has assisted 443 students in applying and matriculating to graduate school. Using program evaluation data from 2020 to 2021, we highlight areas in graduate school admissions that can be improved to promote equity and inclusion.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37595563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37595563</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.029>10.1016/j.cell.2023.07.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37595563</guid><pubDate> Fri, 18 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Melissa Andrea Cadena</dc:creator><dc:creator> Cathy Amaya</dc:creator><dc:creator> Daisy Duan</dc:creator><dc:creator> Carlos Alberto Rico</dc:creator><dc:creator> Leonor García-Bayona</dc:creator><dc:creator> Aníbal Tornes Blanco</dc:creator><dc:creator> Yessica Santana Agreda</dc:creator><dc:creator> Gonzalo Javier Villegas Rodríguez</dc:creator><dc:creator> Alexis Ceja</dc:creator><dc:creator> Vianna G Martinez</dc:creator><dc:creator> Olivia V Goldman</dc:creator><dc:creator> Robert W Fernandez</dc:creator><dc:date> 2023-08-18</dc:date><dc:source> Cell</dc:source><dc:title> Insights and strategies for improving equity in graduate school admissions</dc:title><dc:identifier> pmid:37595563</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.029</dc:identifier></item><item><title> RNA &quot;COURIERs&quot;: Enabling synthetic cell-to-cell communication in human cells</title><link/> https://pubmed.ncbi.nlm.nih.gov/37595562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230822140933&amp;v=2.17.9.post6+86293ac<description> The development of molecular couriers to selectively package, export, and recover RNA molecules within human cells is a significant challenge. In this issue of Cell, Horns et al.¹ introduce cellular RNA exporters, termed COURIERs, that package, secrete, and protect RNA cargo and establish the foundation for sophisticated cell-to-cell RNA communication. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 17;186(17):3526-3528. doi: 10.1016/j.cell.2023.07.030.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The development of molecular couriers to selectively package, export, and recover RNA molecules within human cells is a significant challenge. In this issue of Cell, Horns et al. <sup>1</sup> introduce cellular RNA exporters, termed COURIERs, that package, secrete, and protect RNA cargo and establish the foundation for sophisticated cell-to-cell RNA communication.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37595562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230822140933&v=2.17.9.post6+86293ac">37595562</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.030>10.1016/j.cell.2023.07.030</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37595562</guid><pubDate> Fri, 18 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Taek Kang</dc:creator><dc:creator> Leonidas Bleris</dc:creator><dc:date> 2023-08-18</dc:date><dc:source> Cell</dc:source><dc:title> RNA &quot;COURIERs&quot;: Enabling synthetic cell-to-cell communication in human cells</dc:title><dc:identifier> pmid:37595562</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.030</dc:identifier></item></channel></rss>